24-Apr-2009 - febit holding gmbh

febit Receives European Patent for Gene Extraction Procedure

febit holding gmbh announced, that the company has been granted the first European patent (EP1436609) for a microarray-based nucleic acid extraction procedure. In conjunction with the US patent US7320862, febit now holds a unique patent position in the dynamic market of sample preparation for second-generation sequencers.

The new patent refers to a technology that has already been successfully used for a novel method directed at the selection and enrichment of DNA for re-sequencing purposes. This technology substantially enhances the efficiency of high-throughput re-sequencing and renders it suitable for a broad spectrum of applications in medical and biological studies.

Targeted re-sequencing of medically relevant genomic loci enables fundamentally new approaches to research normal cellular functions and pathological changes observed in major diseases such as cancer and Alzheimer´s disease. The results of these investigations will allow the development of novel diagnostic tests and provide a greatly enhanced specificity of drug therapies. febit´s microfluidic Geniom Biochips have been used successfully for several years in analysis and synthesis of DNA.

febit holds a broad portfolio of 20 granted patents for numerous applications. The first applications for microarray-based extraction procedures were filed back in 2001. Besides bioanalytics, the portfolio predominantly covers biochip-based production of synthetic genes. In this field, febit holds key patents that were successfully used in a recent controversy with a competing U.S. company. Using a focussed application strategy, febit has been able to secure important product components, processes, and advancements.

More about Febit
  • News

    febit Announces Operational Restructuring

    febit announced a restructuring as a consequence of its strategic focus on blood-based microRNA biomarker discovery, febit’s major business development in 2009/2010, and on partnerships and intellectual property (IP) commercialization. The new focus includes the collaboration and provision ... more

    febit Receives European Union (EU) Patent for Synthesis of Minimal Genomes

    febit announced the receipt of an EU patent, #EP 1 728 860B1, for its technology to synthesize minimal genomes. The new patent protects febit’s technology for combining genes to construct a minimal functional genome or parts of it. The EU patent complements earlier patents on the synthesis ... more

    febit Launches Whole Genome Sequencing Service in Europe

    febit announced that the company now offers whole genome sequencing services in Europe for a broad range of species. febit has acquired two Applied Biosystems SOLiD™ high-throughput sequencing systems from Life Technologies Corporation, necessary for whole genome resequencing. One of the tw ... more

  • Companies

    febit Inc.

    febit is the company that puts the control for simplified genomic research in the hands of its customers - where it belongs. The automation of DNA synthesis and analysis and the superior support in bioinformatics helps to understand data and turn it into results. more